Proton pump inhibitor

Phase 3Small molecule

AAVM Biotechnology Inc

Proton pump inhibitor is one of 60 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

RefluxWithdrawn

Helicobacter PyloriRecruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

RefluxPreclinical

Withdrawn

Helicobacter PyloriPhase 3

Recruiting

Competition

Competitive Landscape

90 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Levophed

GGeneral Hospital of Ningxia Medical University

Approved

3 2

Glypressin

MMallinckrodt

Approved

2 3

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—4

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 5

Oraverse

LLife Extension Foundation Inc.

Phase 3

1 6

Lamisil

Novartis

Phase 2

1 7

Northera

Lundbeck

Phase 2

1 8

Pitressin

AAultman Health Foundation

Phase 2

1 9

Proton pump inhibitor

AAVM Biotechnology Inc

Phase 3

1 10

Arginine Vasopressin

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Helicobacter Pylori

NCT04415983

Clinical

Trials by Indication[1]

Helicobacter Pylori Infection3 trials

Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01742429·200 enrolled

Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection

Recruiting·TTanta University·N/A·NCT07165444·320 enrolled

Empirical Rescue Therapies of Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01668927·424 enrolled

Occlusion1 trial

PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

Completed·UUniversity Medical Center Goettingen··NCT05817721·893 enrolled

Acute Kidney Injury1 trial

Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury

Completed·QQianfoshan Hospital··NCT05533619·30,000 enrolled

Gastric Cancer1 trial

The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding

Terminated·NNational Cancer Center, Korea·Phase 3·NCT02150447·394 enrolled

Chronic Cough1 trial

Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux

Withdrawn·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT00771706

13 more indications

Hearing Loss1 trial

Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation

Unknown status·NNational Taiwan University Hospital·Phase 2/3·NCT00789061·120 enrolled

Pain1 trial

Pain After Endoscopic Submucosal Dissection

Completed·GGangnam Severance Hospital·N/A·NCT02254889·156 enrolled

Peptic ulcer1 trial

Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis

Terminated·TTaipei Veterans General Hospital, Taiwan·Phase 2/3·NCT04140591·10 enrolled

Fatigue1 trial

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Unknown status·CClinical Research Support Center Kyush·Phase 2·NCT02288078·74 enrolled

Lymphoma1 trial

Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation

Unknown status·TTechnische Universität Dresden·Phase 3·NCT00154440·200 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Completed·FForest Laboratories·Phase 3·NCT00559364·50 enrolled

Thyroid1 trial

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Completed·IIBSA Institut Biochimique SA·Phase 4·NCT03094416·66 enrolled

GERD1 trial

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Unknown status·SSamsung Medical Center·N/A·NCT00539786·100 enrolled

Intravenous1 trial

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

Completed·UUniversity of Southern California·N/A·NCT00573924·66 enrolled

Gastric1 trial

Nordic Gastric and Esophageal Tumor Study

Completed·KKarolinska Institutet··NCT05688761·900,000 enrolled

Reflux1 trial

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

Withdrawn·VVirginia Commonwealth University·N/A·NCT02039869

Helicobacter Pylori1 trial

Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

Recruiting·TTanta University·Phase 3·NCT04415983·100 enrolled

Glioblastoma1 trial

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available·AAVM Biotechnology Inc··NCT05974410

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Proton pump inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proton pump inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proton pump inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AVM Biotechnology Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAVM Biotechnology Inc

Proton pump inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Helicobacter Pylori Infection3 trials

Occlusion1 trial

Acute Kidney Injury1 trial

Gastric Cancer1 trial

Chronic Cough1 trial

Hearing Loss1 trial

Pain1 trial

Peptic ulcer1 trial

Fatigue1 trial

Lymphoma1 trial

Safety and Efficacy1 trial

Thyroid1 trial

GERD1 trial

Intravenous1 trial

Gastric1 trial

Reflux1 trial

Helicobacter Pylori1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News